Patents by Inventor Francisca Delgado-Jimenez
Francisca Delgado-Jimenez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210300900Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 30, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Francisca Delgado-Jiménez, Ana Isabel De Lucas Olivares, Juan Antonio Vega Ramiro
-
Publication number: 20210277015Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez-Viturro, Francisca Delgado-Jiménez, Susana Conde-Ceide, Juan Antonio Vega Ramiro
-
Publication number: 20210122763Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: April 29, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Ana Isabel De Lucas Olivares, Francisca Delgado-Jiménez, Susana Conde-Ceide, Juan Antonio Vega Ramiro
-
Patent number: 9845326Abstract: The present invention relates to novel 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives of formula (I) wherein R1, R2, R3, R4, X1, X2, X3, X4, L, and Ar are defined in the specification, as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: GrantFiled: March 7, 2012Date of Patent: December 19, 2017Assignee: Janssen Pharmaceutica NVInventors: Andrés Avelino Trabanco-Suárez, Francisca Delgado-Jiménez
-
Patent number: 9840507Abstract: The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine inhibitors of beta-secretase, having the structure shown in Formula (I) wherein R1, R2, R3, R4, X1, X2, X3, X4, L and Ar are defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebrovascular amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: GrantFiled: December 21, 2011Date of Patent: December 12, 2017Assignee: Janssen Pharmaceutica, NVInventors: Andrés Avelino Trabanco-Suárez, Francisca Delgado-Jiménez, Juan Antonio Vega Ramiro, Gary John Tresadern, Henricus Jacobus Maria Gijsen, Daniel Oehlrich
-
Patent number: 9346811Abstract: The present invention relates to novel 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: GrantFiled: February 29, 2012Date of Patent: May 24, 2016Assignee: JANSSEN PHARMACEUTICA NVInventors: Andrés Avelino Trabanco-Suárez, Henricus Jacobus Maria Gijsen, Michiel Luc Maria Van Gool, Juan Antonio Vega Ramiro, Francisca Delgado-Jiménez
-
Publication number: 20140005200Abstract: The present invention relates to novel 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: ApplicationFiled: February 9, 2012Publication date: January 2, 2014Applicant: Janssen Pharmaceutica NVInventors: Andrés Avelino Trabanco-Suárez, Henricus Jacobus Maria Gijsen, Michiel Luc Maria Van Gool, Juan Antonio Vega Ramiro, Francisca Delgado-Jiménez
-
Publication number: 20130345228Abstract: The present invention relates to novel 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: ApplicationFiled: March 7, 2012Publication date: December 26, 2013Applicant: JANSSEN PHARMACEUTICAL NVInventors: Andrés Avelino Trabanco-Suárez, Francisca Delgado-Jiménez
-
Patent number: 8609660Abstract: The present invention relates to novel 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: GrantFiled: September 20, 2011Date of Patent: December 17, 2013Assignee: Janssen Pharmaceutica NVInventors: Andrés Avelino Trabanco-Suárez, Gary John Tresadern, Francisca Delgado-Jiménez
-
Publication number: 20130274266Abstract: The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebrovascular amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicant: Janssen Pharmaceutica NVInventors: Andres Avelino Trabanco-Suárez, Francisca Delgado-Jiménez, Juan Antonio Vega Ramiro, Gary John Tresadern, Henricus Jacobus Maria Gijsen, Daniel Oehlrich
-
Patent number: 8530474Abstract: The present invention is concerned with novel substituted 6-(1-piperazinyl)-pyridazines of Formula (I) wherein R1, R2, R3 and X have the meaning defined in the claims, having 5-HT6-antagonistic properties. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel compound as an active ingredient as well as the use of said compounds as a medicine.Type: GrantFiled: July 1, 2009Date of Patent: September 10, 2013Assignee: Janssen Pharmaceutica NVInventors: José Manuel Bartolomé-Nebreda, Gregor James MacDonald, Michiel Luc Maria Van Gool, Susana Conde-Ceide, Francisca Delgado-Jiménez
-
Publication number: 20130190318Abstract: The present invention relates to novel 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: ApplicationFiled: September 20, 2011Publication date: July 25, 2013Applicant: Janssen Pharmaceutica NVInventors: Andrés Avelino Trabanco-Suárez, Gary John Tresadern, Francisca Delgado-Jiménez
-
Publication number: 20130102618Abstract: The present invention relates to novel 3-amino-5,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.Type: ApplicationFiled: June 27, 2011Publication date: April 25, 2013Applicant: JANSSEN PHARMACEUTICA NVInventors: Francisca Delgado-Jiménez, Gary John Tresadern, Andrés Avelino Trabanco-Suárez
-
Publication number: 20110112107Abstract: The present invention is concerned with novel substituted 6-(1-piperazinyl)-pyridazines of Formula (I) wherein R1, R2, R3 and X have the meaning defined in the claims, having 5-HT6-antagonistic properties. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel compound as an active ingredient as well as the use of said compounds as a medicine.Type: ApplicationFiled: July 1, 2009Publication date: May 12, 2011Inventors: José Manuel Bartolomé-Nebreda, Gregor James MacDonald, Michiel Luc Maria Van Gool, Susana Conde-Ceide, Francisca Delgado-Jiménez
-
Publication number: 20100137368Abstract: The present invention relates to (1-benzyl-piperidin-4-yl)-(pyridin-2-yl)-amines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.Type: ApplicationFiled: April 18, 2008Publication date: June 3, 2010Applicant: JANSSEN PHARMACEUTICA N.V.Inventors: Gregor James MacDonald, José Manuel Bartolomé-Nebreda, Michiel Luc Maria Van Gool, Francisca Delgado-Jiménez
-
Publication number: 20100105694Abstract: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim 1, having selective 2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.Type: ApplicationFiled: October 10, 2007Publication date: April 29, 2010Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Maria Lourdes Linares De La Morena, Sonia Martinez Gonzalez, Julen Oyarzabal Santamarina, Joaquin Pastor-Fernández, Juan Antonio Vega-Ramiro, Francisca Delgado-Jiménez, Wilhelmus Helena Ignatius Maria Drinkenburg
-
Publication number: 20090281099Abstract: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective ?2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.Type: ApplicationFiled: May 21, 2007Publication date: November 12, 2009Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Maria Lourdes Linares De La Morena, Sonia Martinez Gonzalez, Julen Oyarzabal Santamarina, Joaquin Pastor-Fernàndez, Juan Antonio Vega Ramiro, Francisca Delgado-Jiménez, Wilhelmus Helena Drinkenburg
-
Publication number: 20090111801Abstract: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective ?2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.Type: ApplicationFiled: April 19, 2007Publication date: April 30, 2009Applicant: Janssen Pharmaceutica N.V.Inventors: Jose Ignacio Andres-Gil, Manuel Jesus Alcazar-Vaca, Maria Lourdes Linares De La Morena, Sonia Martinez Gonzalez, Julen Oyarzabal Santamarina, Joaquin Pastor-Fernandez, Juan Antonio Vega Ramiro, Francisca Delgado-Jimenez, Wilhelmus Helena Ignatius Maria Drinkenburg